# US 2024/0254169 A1 · Protein and peptide delivery systems and methods for making and using them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254169 A1
- Document ID: US20240254169A1
- Status: Published application
- Kind: A1
- Application number: 17/294,656
- Filed: 2019-11-15
- Published: 2024-08-01
- Earliest claimed: 2018-11-16
- Assignees: San Diego State University (Sdsu) Foundation, Dba San Diego State University Research Foundation; J. Craig Venter Institute, Inc.; ETH Zurich
- Applicants: San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation; J. Craig Venter Institute; Eth Zurich
- Inventors: Nicholas J. SHIKUMA; Sinem BEYHAN; Martin PILHOFER; Charles ERICSON
- Web page: https://patentgrep.com/patent/US20240254169A1

## CPC

- C07K 14/195: from bacteria
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided are compositions, kits, and methods for delivering a proteinaceous cargo, or a protein or a peptide, or a drug or a marker, to or into a cell or to an individual in need thereof. Methods comprise use of: a substantially purified or isolated bacterial Contractile Injection Systems (CIS) or Metamorphosis Associated Contractile structure; a recombinant bacterial Contractile Injection Systems (CIS) or Metamorphosis Associated Contractile structure (MACs); a liposome or lipid-comprising nanoparticle incorporating or expressing on its outer surface the substantially purified or isolated bacterial CIS or MACs, or the recombinant bacterial CIS or MACs; a protoplast or a spheroplast incorporating or expressing on its outer surface the substantially purified or isolated bacterial CIS or MACs, or the recombinant bacterial CIS or MACs; a cell expressing on its extracellular surface the substantially purified or isolated bacterial CIS or MACs, or the recombinant bacterial CIS or MACs.

## Claims

### Claim at position 1

1: A recombinant bacterial Contractile Injection Systems (CIS) or a Metamorphosis Associated Contractile structure (MACs),
wherein the recombinant bacterial CIS or MACs comprise or have contained therein a proteinaceous cargo, or a heterologous protein or peptide,
and the proteinaceous cargo, or a heterologous protein or peptide comprises a Metamorphosis-Inducing Factor 1 (Mif1) protein, or is linked to a Mif1 (optionally is chemically linked or electrostatically linked), or is a fusion or a recombinant protein comprising a Mif1,
wherein the Mif1 protein is encoded by a nucleic acid sequence having at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 100% sequence identity to SEQ ID NO: 1, or between about 80% to 100% sequence identity to SEQ ID NO: 1,
or the Mif1 protein comprises a sequence having at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 100% sequence identity to SEQ ID NO:2, or between about 80% to 100% sequence identity to SEQ ID NO:2.

### Claim at position 2

2: A liposome or lipid-comprising nanoparticle incorporating or expressing on its outer surface a substantially purified or isolated bacterial CIS or MACs, or a recombinant bacterial CIS or MACs,
wherein the substantially purified or isolated bacterial CIS, or the recombinant bacterial CIS or MACs, comprise or have contained therein a proteinaceous cargo, or a heterologous protein or peptide,
and the proteinaceous cargo, or a heterologous protein or peptide comprises a Metamorphosis-Inducing Factor 1 (Mif1) protein, or is linked to a Mif1 (optionally is chemically linked or electrostatically linked), or is a fusion or a recombinant protein comprising a Mif1,
wherein the Mif1 protein is encoded by a nucleic acid sequence having at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 100% sequence identity to SEQ ID NO: 1, or between about 80% to 100% sequence identity to SEQ ID NO: 1,
or the Mif1 protein comprises a sequence having at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 100% sequence identity to SEQ ID NO:2, or between about 80% to 100% sequence identity to SEQ ID NO:2.

### Claim at position 3 (depends on 1)

3: A protoplast or a spheroplast incorporating or expressing on its outer surface a substantially purified or isolated bacterial CIS or MACs, or a recombinant bacterial CIS or MACs, of claim 1.

### Claim at position 4 (depends on 1)

4: A cell expressing on its extracellular surface a substantially purified or isolated bacterial CIS or MACs, or a recombinant bacterial CIS or MACs, of claim 1
wherein the CIS or MACs are heterologous to the cell,
wherein the cell is a microbial cell or a eukaryotic cell, and optionally the microbial cell is a bacterial cell.

### Claim at position 5 (depends on 1)

5: A method for delivering a proteinaceous cargo, or a protein or a peptide, or a drug or a marker, to a cell, optionally to a eukaryotic, mammalian or human cell, or to a plant cell, or to an individual in need thereof, comprising:
(a) providing a formulation or composition comprising:
(i) a substantially purified or isolated bacterial Contractile Injection Systems (CIS) or Metamorphosis Associated Contractile structure (MACs) of claim 1;
(ii) a recombinant bacterial Contractile Injection Systems (CIS) or Metamorphosis Associated Contractile structure (MACs) of claim 1;
(iii) a liposome or lipid-comprising nanoparticle incorporating or expressing on its outer surface the substantially purified or isolated bacterial CIS or MACs, or the recombinant bacterial CIS or MACs of claim 1;
(iv) a protoplast or a spheroplast incorporating or expressing on its outer surface the substantially purified or isolated bacterial CIS or MACs, or the recombinant bacterial CIS or MACs of claim 1;
(v) a cell expressing on its extracellular surface the substantially purified or isolated bacterial CIS or MACs, or the recombinant bacterial CIS or MACs of claim 1; or
(vi) any combination of (i) to (v);
(b) contacting the formulation or composition with the cell under conditions wherein the formulation or composition, or the proteinaceous cargo, or the protein or peptide, contacts or interacts with the cell, thereby delivering the proteinaceous cargo, or the protein or peptide to or into the cell.

### Claim at position 6 (depends on 5)

6: The method of claim 5, wherein the proteinaceous cargo, or the protein or peptide, comprises or is an antibody, an enzyme, a drug, a marker, a detectable moiety, or an active biological agent.

### Claim at position 7 (depends on 5)

7: The method of claim 5, wherein the contacting of the formulation or composition with the cell eukaryotic cell is in vitro, ex vivo, or in vivo.

### Claim at position 8 (depends on 5)

8: The method of claim 5, wherein the eukaryotic cell is a mammalian, human or an animal cell.

### Claim at position 9 (depends on 1)

8: A kit comprising: a formulation or composition comprising:
(i) a substantially purified or isolated bacterial Contractile Injection Systems (CIS) or Metamorphosis Associated Contractile structure (MACs) of claim 1;
(ii) a recombinant bacterial Contractile Injection Systems (CIS) or Metamorphosis Associated Contractile structure (MACs) of claim 1;
(iii) a liposome or lipid-comprising nanoparticle incorporating or expressing on its outer surface the substantially purified or isolated bacterial CIS or MACs, or the recombinant bacterial CIS or MACs, of claim 1;
(iv) a protoplast or a spheroplast incorporating or expressing on its outer surface the substantially purified or isolated bacterial CIS or MACs, or the recombinant bacterial CIS or MACs, of claim 1;
(v) a cell expressing on its extracellular surface the substantially purified or isolated bacterial CIS or MACs, or the recombinant bacterial CIS or MACs, of claim 1,
wherein optionally the cell is a microbial cell or a eukaryotic cell, or a mammalian or a human cell, and optionally the microbial cell is a bacterial cell; or
(vi) any combination of (i) to (v).

### Claim at position 10

10-11. (canceled)

### Claim at position 11 (depends on 5)

12: The method of claim 5, wherein the cell is a microbial cell or a eukaryotic cell.

### Claim at position 12 (depends on 12)

13: The method of claim 12, wherein the eukaryotic cell is a mammalian or a human cell, or the microbial cell is a bacterial cell
